Abstract
Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenomics of Open-Angle Glaucoma
Volume: 6 Issue: 2
Author(s): Stephen G. Schwartz, Juan A. Ayala-Haedo, Krishna S. Kishor and M. Elizabeth Fini
Affiliation:
Abstract: Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Export Options
About this article
Cite this article as:
Schwartz G. Stephen, Ayala-Haedo A. Juan, Kishor S. Krishna and Fini Elizabeth M., Pharmacogenomics of Open-Angle Glaucoma, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020121
DOI https://dx.doi.org/10.2174/1875692110806020121 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Proteomic Analysis of the Vitreous Body in Proliferative and Non-Proliferative Diabetic Retinopathy
Current Proteomics Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Structure and Function of Myelinated Nerve Fibers in the Rabbit Eye Following Ischemia/Reperfusion Injury
Current Neurovascular Research Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Microcirculation of the Diabetic Foot
Current Pharmaceutical Design The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging